vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and REGIS CORP (RGS). Click either name above to swap in a different company.
REGIS CORP is the larger business by last-quarter revenue ($57.1M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). REGIS CORP runs the higher net margin — 0.8% vs -3.7%, a 4.5% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 22.3%). REGIS CORP produced more free cash flow last quarter ($891.0K vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 7.8%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
GYRE vs RGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $57.1M |
| Net Profit | $-1.4M | $456.0K |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 10.8% |
| Net Margin | -3.7% | 0.8% |
| Revenue YoY | 33.4% | 22.3% |
| Net Profit YoY | -340.1% | -94.0% |
| EPS (diluted) | $-0.01 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $57.1M | ||
| Q3 25 | $30.6M | $59.0M | ||
| Q2 25 | $26.8M | $60.4M | ||
| Q1 25 | $22.1M | $57.0M | ||
| Q4 24 | $27.9M | $46.7M | ||
| Q3 24 | $25.5M | $46.1M | ||
| Q2 24 | $25.2M | $49.4M | ||
| Q1 24 | $27.2M | $49.2M |
| Q4 25 | $-1.4M | $456.0K | ||
| Q3 25 | $5.9M | $1.4M | ||
| Q2 25 | $1.6M | $116.5M | ||
| Q1 25 | $3.7M | $250.0K | ||
| Q4 24 | $569.0K | $7.6M | ||
| Q3 24 | $2.9M | $-853.0K | ||
| Q2 24 | $4.5M | $91.2M | ||
| Q1 24 | $9.9M | $-2.3M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 10.8% | ||
| Q3 25 | 22.7% | 10.0% | ||
| Q2 25 | 8.1% | 12.1% | ||
| Q1 25 | 10.3% | 8.8% | ||
| Q4 24 | 2.4% | 11.8% | ||
| Q3 24 | 16.6% | 4.6% | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 29.7% | 8.3% |
| Q4 25 | -3.7% | 0.8% | ||
| Q3 25 | 19.4% | 2.3% | ||
| Q2 25 | 5.9% | 192.9% | ||
| Q1 25 | 16.9% | 0.4% | ||
| Q4 24 | 2.0% | 16.4% | ||
| Q3 24 | 11.2% | -1.9% | ||
| Q2 24 | 18.0% | 184.7% | ||
| Q1 24 | 36.6% | -4.7% |
| Q4 25 | $-0.01 | $0.16 | ||
| Q3 25 | $0.03 | $0.49 | ||
| Q2 25 | $0.00 | $43.67 | ||
| Q1 25 | $0.00 | $0.08 | ||
| Q4 24 | $0.00 | $2.71 | ||
| Q3 24 | $0.01 | $-0.36 | ||
| Q2 24 | $0.01 | $38.40 | ||
| Q1 24 | $0.03 | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $106.0M | $188.7M |
| Total Assets | $166.1M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $18.4M | ||
| Q3 25 | $60.0M | $16.6M | ||
| Q2 25 | $54.4M | $17.0M | ||
| Q1 25 | $29.9M | $13.3M | ||
| Q4 24 | $26.7M | $10.2M | ||
| Q3 24 | $25.1M | $6.3M | ||
| Q2 24 | $25.1M | $10.1M | ||
| Q1 24 | $37.4M | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | $106.0M | $188.7M | ||
| Q3 25 | $101.9M | $187.6M | ||
| Q2 25 | $92.0M | $185.6M | ||
| Q1 25 | $68.1M | $68.6M | ||
| Q4 24 | $63.3M | $66.7M | ||
| Q3 24 | $63.2M | $56.4M | ||
| Q2 24 | $60.4M | $56.8M | ||
| Q1 24 | $56.6M | $-35.8M |
| Q4 25 | $166.1M | $588.3M | ||
| Q3 25 | $159.4M | $592.1M | ||
| Q2 25 | $152.6M | $599.0M | ||
| Q1 25 | $129.8M | $511.2M | ||
| Q4 24 | $125.4M | $530.1M | ||
| Q3 24 | $125.2M | $508.9M | ||
| Q2 24 | $120.9M | $530.5M | ||
| Q1 24 | $122.0M | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $1.7M |
| Free Cash FlowOCF − Capex | $-5.8M | $891.0K |
| FCF MarginFCF / Revenue | -15.5% | 1.6% |
| Capex IntensityCapex / Revenue | 0.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $1.7M | ||
| Q3 25 | $4.7M | $2.3M | ||
| Q2 25 | $2.1M | $6.8M | ||
| Q1 25 | $-129.0K | $6.2M | ||
| Q4 24 | $-2.8M | $2.1M | ||
| Q3 24 | $1.7M | $-1.3M | ||
| Q2 24 | $-5.5M | $5.1M | ||
| Q1 24 | $2.9M | $-277.0K |
| Q4 25 | $-5.8M | $891.0K | ||
| Q3 25 | $4.0M | $1.9M | ||
| Q2 25 | $1.8M | $6.2M | ||
| Q1 25 | $-251.0K | $5.9M | ||
| Q4 24 | $-2.8M | $1.7M | ||
| Q3 24 | $1.0M | $-1.4M | ||
| Q2 24 | $-6.9M | $5.1M | ||
| Q1 24 | $2.7M | $-326.0K |
| Q4 25 | -15.5% | 1.6% | ||
| Q3 25 | 13.1% | 3.2% | ||
| Q2 25 | 6.8% | 10.3% | ||
| Q1 25 | -1.1% | 10.3% | ||
| Q4 24 | -10.1% | 3.6% | ||
| Q3 24 | 4.1% | -3.0% | ||
| Q2 24 | -27.5% | 10.3% | ||
| Q1 24 | 9.8% | -0.7% |
| Q4 25 | 0.4% | 1.4% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.0% | 0.9% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 2.7% | 0.0% | ||
| Q2 24 | 5.8% | 0.0% | ||
| Q1 24 | 0.9% | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | 0.79× | 1.68× | ||
| Q2 25 | 1.32× | 0.06× | ||
| Q1 25 | -0.03× | 24.80× | ||
| Q4 24 | -4.85× | 0.28× | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | 0.06× | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
